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Since the 2009 pandemic H1N1 swine-origin influenza A virus (09 S-OIV) has reminded the world about the global threat of the 
ever changing influenza virus, many questions regarding the detailed re-assortment of influenza viruses yet remain unanswered. 
Influenza A virus is the causative agent of the pandemic flu and contains 2 major antigenic glycoproteins on its surface: (i) he-
magglutinin (HA); and (ii) neuraminidase (NA). The structures of the 09 S-OIV HA and NA proteins (09H1 and 09N1) have re-
cently been resolved in our laboratory and provide some clues as to why the 09 S-OIV re-assortment virus is highly infectious 
with severe consequences in humans. For example, the 09H1 is highly similar to the HA of the 1918 influenza A pandemic virus 
in overall structure and especially in regards to its 5 defined antibody binding epitopes. For 09N1, its most distinctive feature is 
the lack of a 150-loop active site cavity, which was previously predicted to be present in all N1 NAs, and we hypothesize that the 
150-loop may play a important role in the substrate specificity (α2,3 or α2,6 linked sialic acid receptors) and enzymatic mecha-
nism of influenza NA. Combination of the HA and NA with special characteristics for the 09 S-OIV might contribute to its high 
increased transmissibility in humans. 
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In early 2009, severe cases of H1N1 influenza A virus 
broke out primarily in Mexico. On April 29, 2009, the 
World Health Organization (WHO) raised its alert level for 
this influenza outbreak to Phase 5, the highest level ever 
announced since the warning system was introduced in 
2005 (WHO). By June 11, 2009, this pandemic H1N1 virus 
had officially been reported in 74 countries and the WHO 
alert level was then raised to Phase 6, the pandemic level 
(WHO). In 2010, reports of pandemic H1N1 infection sig-
nificantly declined and on August 10, 2010 the WHO de-
clared that the pandemic was over (WHO). As of August 6,  
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2010, the 2009 pandemic H1N1 had been attributed to the 
deaths of over 18449 individuals (WHO). 
Previous influenza pandemics include the 1918 ‘Spanish 
Flu’ (H1N1), ‘Asian Flu’ of 1957 (H2N2), and ‘Hong Kong 
Flu’ of 1968 (H3N2) [1]. Like the 2009 pandemic virus, the 
1918 virus was also an H1N1 influenza A virus and it is 
estimated to have led to the deaths of over 40 million people 
(WHO). The 1957 H2N2 Asian flu is estimated to have 
killed about 2 million people and the 1968 H3N2 Hong 
Kong flu is estimated to have killed about 1 million people, 
(WHO). Although the 2009 H1N1 virus was raised to the 
pandemic level by the WHO, only about 20000 deaths have 
been attributed to it, comparable to that of the seasonal flu 
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(WHO). However, like the 1918 pandemic virus, the 2009 
pandemic virus often leads to severe respiratory problems in 
young, pregnant and healthy individuals [2]. 
Influenza viruses can be categorized into 3 types: A, B 
and C. Influenza A virus is the causative agent of pandemic 
flu. The influenza A virus genome contains 8 RNA seg-
ments which encode up to 12 proteins: NP, NS1, NS2, M1, 
PA, PB1, PB2, PB1-F2, PB1 N40 and 3 surface proteins, 
M2, HA and NA [1,3]. HA (hemagglutinin) and NA 
(neuraminidase) are the principal influenza surface antigens 
and contain multiple serotypes based upon their antigenicity 
[1]. HA is responsible for sialic acid receptor binding, fa-
cilitating the process of virus and host endosomal mem-
brane fusion and allowing the viral genetic materials to gain 
entry into the cytoplasm [1]. NA, which is a sialidase, cata-
lyzes hydrolysis of terminally linked sialic acid receptors 
and functions as the receptor destroying element of influ-
enza A and B viruses, thereby helping newly formed virions 
to break free from infected cells and to continue infecting 
new cells [1]. HA is grouped into 16 different known sero-
types and NA is grouped into 9 [1,4]. Therefore influenza A 
virus strains are named based upon their combination of HA 
and NA (e.g. H1N1, H5N1, H3N2) [1]. Certain HA/NA 
virus types are highly specific for different animal hosts 
which is promoted, partially, by evolutionary differences in 
host immune systems and host restriction factors [4,5]. For 
example, H5N1 is highly common in birds whereas H3N2 is 
a common seasonal flu strain in humans [5]. Furthermore, 
human seasonal flu strains produce more variation in their 
HA/NA antigenic sites due to a higher selective pressure in 
the human immune system [6].  
During infection of a host with multiple influenza A vi-
rus strains, reassortment of RNA segments from different 
viruses into new budding virions may occur [7]. The 2009 
pandemic swine-origin H1N1 influenza A virus (09 S-OIV) 
is a reassortment with PB2 and PA derived from avian in-
fluenza, PB1 derived from human H3N2, HA, NP and NS 
derived from classical swine H1N1, and NA and M derived 
from a Eurasian avian like swine H1N1 influenza lineage 
[8–10]. Both the 1957 H2N2 pandemic and the 1968 H3N2 
pandemic were also reassortments between avian and hu-
man viruses [11]. Highly pathogenic avian influenza vi-
ruses, such as H5N1 are often very deadly to humans, how-
ever infection of human with these avian influenza viruses 
is rare [12] Recently it has been confirmed that multiple 
reassortments of avian H5N1 with human H3N2 can lead 
increased virulence in mice [13]. It is therefore a serious 
concern that highly pathogenic avian influenza strains may 
gain higher transmissibility in humans through an interme-
diate mixing vessel; especially swine [14].  
According to the current understanding of influenza virus 
interspecies transmission, swine may act as a primary mix-
ing vessel between avian and human virus strains [14]. HA 
and NA receptor specificities likely play an integral role in 
determining the basis for influenza host specificity. In gen-
eral, avian hosts primarily contain α2,3 linked sialic acid 
receptors and avian influenza virus preferentially binds the 
α2,3 receptor, however the upper respiratory tract of hu-
mans contains primarily α2,6 linked sialic acid receptors 
[15–17]. This may explain why human influenza viruses 
preferentially bind the α2,6 receptor and is considered a 
major reason why avian influenza virus is not highly trans-
missible in humans. Swine contain both α2,3 and α2,6 
linked sialic acid receptors in their respiratory system and 
possess a less complex immune system than humans, which 
may explain why they are more susceptible to infection by 
avian and human strains of influenza and why swine influ-
enza viruses may easily evolve the ability to bind the human 
α2,6 receptor [15–17]. The recent 2009 pandemic H1N1 is 
the first pandemic influenza re-assortment virus with a pri-
marily swine-influenza origin, which is a major reason why 
it has caused great concern [18–21].  
Although other influenza proteins like PB1 and PB2 also 
play an important role in pathogenicity, HA and NA are on 
the front line of the process of virus entry, fusion and re-
lease of progeny virions. Furthermore, these two viral en-
velope glycoproteins are the primary targets of the immune 
system and interact directly with the receptors, and there-
fore are critical elements in determining host cell specificity 
[1,4]. For these reasons, the unique properties of the 09H1 
and 09N1 can provide many insights into the increased 
transmissibility and pathogenicity of the 09 S-OIV. 
1  HA 
HA binds primarily to α2,3 or α2,6 linked sialic acid re-
ceptors on the mammalian cell surface acting as the receptor 
binding element of type A and B influenza viruses [1,4]. 
The receptor binding function of HA is the first step of the 
influenza infection cycle and there has been a great deal of 
research into its function [22]. The sialic acid binding site is 
located in the head region of each HA molecule [22]. Influ-
enza HA contains various N-glycosylation sites and is se-
creted as a homotrimer to the membrane/viral envelope 
where it is anchored via transmembrane helices [22,23]. 
Cleavage of each HA monomer into two polypeptides, HA1 
and HA2, by cellular proteases is necessary for HA to fa-
cilitate host-virus membrane fusion [22].  
Sequence analysis indicates that 09H1 has recently 
evolved and that two major subtypes of 09 S-OIV emerged, 
with a Mexico and New York origin [24,25]. The structure 
of 09HA has been reported by several research groups and 
the detailed structure is strikingly similar to 1918 pandemic 
H1 HA (18H1) [6,26,27]. The similarity is especially pro-
nounced in regards to the 5 defined antibody binding sites 
[6,7]. This can explain why older generations which have 
been exposed to the 1918 pandemic H1N1 have resistance 
to 09 S-OIV [26]. In a similar manner, it has recently been 
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reported that survivors of the 09 S-OIV have acquired an 
effective immune response against many influenza strains 
[28]. Furthermore, neither 18H1 nor 09H1 contain con-
served N-glycosylation sites in the head region which may 
interfere with receptor binding and the lack of N-glcosyl- 
ation in the head region has been shown to increase their 
receptor binding affinities [29]. 
Another primary similarity of 18H1 with 09H1 is the 
sialic acid receptor specificity, which is the critical deter-
minant of host range as demonstrated in numerous previous 
studies [30,31]. Most importantly, the 190 and 225 residues 
(all HA residues here are H1 numbered) have been identi-
fied to play a predominant role in determining binding 
specificity of H1 [32]. For 09H1, the Asp190/Asp225 pair is 
responsible for specifically recognizing only the α2,6 hu-
man receptor (unpublished data), whereas other matching 
patterns such as Glu190/Gly225 and Asp190/Gly225 are 
regarded as crucial factors for binding α2,3 receptors in 
avian hosts and both receptors in swine, respectively 
[22,33,34]. Moreover, recent analysis using glycan mi-
croarrays also has revealed that Asp225Glu/Gly substitution 
results in slightly or moderately enhanced binding affinity 
towards a broader range of different α2,3 receptor analogs 
[35]. Based on the binding modes in 30H1 and 34H1 with 
the human and avian receptors [32], 09H1 with the Gly225 
substitution may bind to both human and avian receptors 
[36]. Regarding the Asp225Glu substitution, it was hy-
pothesized that the longer glutamate side chain might fa-
cilitate the interactions with Gal-2 of the α2,3 avian recep-
tor [36], however, in our recent unpublished studies, the 
Asp225Glu mutant of 09H1 preferentially binds to the α2,6 
human receptor due to a different mechanism. 
09H1 contains additional special features worth men-
tioning that distinguish it from other HA proteins, including 
18H1. For example, 09H1 contains larger basic patches 
relative to all other reported HA structures (Figure 1) [6]. 
The His/Lys basic patch is also relatively strong in the 18H1 
structure and is hypothesized to be involved in facilitating 
membrane fusion [36,37]. Additionally, there is an extra 
N-glycosylation site in 09H1 close to this very basic patch 
(Figure 1) [6]. This N-glycosylation site may modulate the 
effect of the stronger basic patch or may play a role in 
masking antibody recognition. The precise effects of the 
basic patch and additional N-glycosylation site on the func-
tion of HA deserve further research and investigation. 
2  NA 
There are currently 9 different serotypes of NA, which can 
be further classified into two separate groups based upon 
phylogenetic sequence analysis. Group 1 consists of N1, 
N4, N5 and N8, and group 2 consists of N2, N3, N6, N7 and 
N9 [38]. Before the structure of 09N1 was released, all pub-
lished group 1 neuraminidase structures contained an addi-
tional 150-loop cavity, which is not present in all other cur-
rently reported group 2 neuraminidase structures [38]. This 
led to the correlation of this structural feature with the pri-
mary sequence of NA [38]. However, our recent work has 
revealed that the 09N1 crystal structure actually does not 
contain the 150-loop cavity (Figure 2) [39]. This indicates 
that the formation of the 150-cavity (at least in the crystal 
state) may possibly be influenced by a single amino acid at 
position 149 (Ile or Val, all NA numbering here is based on 
N2) and its coordination with the 430-loop, rather than en-
tire NA amino acid sequence [39]. Nevertheless, in the case 
of N2 structures, a salt bridge between Asp147 and His150 
appears to be the major factor in stabilizing the 150-loop in 
its closed conformation [39]. Still, the 150-loop is likely 
very flexible and should adopt various open and closed 
conformations in solution [40]. However, the 09N1 
150-loop may be thought of as an intermediate between the 
typical group 1 NAs with the 150-loop cavity in their crystal 
structures and typical group 2 NAs with no 150-loop cavity. 
There is a highly conserved network of electrostatic in-
teractions between the NA active site and its ligand, sialic 
acid, consisting of residues Arg118, Glu119, Asp151, 
Arg152, Trp178, Arg224, Glu276, Glu277, Arg292, Arg371 
and Tyr406. These amino acid residues are 100% conserved 
in all of the current available NA structures from both 
groups (although Arg292 is replaced by Lys in an artificial 
drug resistant Australia N9 strain) [41,42]. Most of these 
residues are involved in substrate binding or may stabilize 
the enzymatic transition state; however Asp151, which is in 
the 150-loop, and Tyr406 are likely to directly participate in 
the catalytic mechanism (based upon mechanistic studies in 
bacterial NA), although it is possible that water molecules 
may replace the function of these two residues leading to 
alternative mechanisms [41,43–45].  
 
Figure 1  Overall structure of 09H1 with an emphasis on the classical 
antigenic sites, second basic patch and N-glycosylation sites adjacent to the 
second basic patch. Modified from Zhang et al. [6] (with permission from 
Protein & Cell). 
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We hypothesize that the 150-loop is important for sub-
strate binding and that the conformation of the 150-loop 
plays an important role in determining the specificity of NA 
for α2,3 or α2,6 linked sialic acid. The ability to obtain the 
first sialic acid complex structure with a group 1 NA using 
09N1 may indicate the importance of the 150-loop in sub-
strate binding (unpublished data). The 150-loop of influenza 
NA contains a strictly conserved Asp151 residue, which we 
also hypothesize may be directly involved in the sialiside 
hydrolase mechanism of influenza NA. In the influenza 
NA-sialic acid complex structures, Asp151 participates in 
multiple hydrogen bonds with sialic acid, including the 
anomeric hydroxyl, which forms the glycosidic bond in the 
α2,3 or α2,6 receptor. Asp151 in the NA structures with an 
open 150-loop conformation is shifted over 1 Å from the 
sialic acid binding site relative to the structures with a 
closed 150-loop conformation (Figure 3). Based on these 
observations, we propose a 3 step model: (i) the flexible 
150-loop may assist binding of α2,3 or α2,6 linked sub-
strate in the open conformation; (ii) hydrolysis of the glyco-
sidic bond may be facilitated by movement of the loop back 
toward the substrate via Asp151; and (iii) release of product 
sialic acid via movement of the 150-loop into the open con-
formation. In this way the 150-loop may act as a switch 
between substrate binding, subsequent NA activity and re-
lease of product sialic acid. We speculate that 09N1 may be 
like an intermediate state between the typical group 1 
(150-cavity) and group 2 (no 150-cavity) structural types 
and this special feature of 09N1 may confer some advantage 
to the 2009 H1N1 pandemic virus which is highly transmis-
sible in humans. Clearly, more detailed biochemical and 
structural studies are needed to test these hypotheses. 
3  Discussion and perspective 
Because HA and NA bind sialic acid in an independent 
manner, it should not be possible that NA cleaves the sialic 
acid glycosidic bond while it is bound to HA. Therefore, 
there must be a critical balance between the expression lev-
els, substrate binding, specificities and activities of each 
HA-NA pair. If the affinity of HA to its receptor is too high 
relative to the NA affinity toward the same receptor, the 
virus will be efficient at infecting new cells, but ineffective 
 
Figure 2  Overall structure of the 09N1 tetramer (a) and comparison of the active sites of 09N1, 18N1, N9 and N2, illustrating the 150-cavity deficient 
active site of 09N1 (b). 
 
Figure 3  Comparison of 150-loop orientations and the position of 
Asp151 using structures from all the currently available NA serotypes in 
the protein data bank (PDB) (N4, N8, 18N1 and avian N1 with an open 
150-loop conformation; N2, N6, N9 and 09N1 with a closed 150-loop 
conformation). The distance between Asp151 in the open and closed con-
formations is over 1 Å. Sialic acid (yellow) is included from the Tokyo N2 
structure (2BAT). Conserved Asp151 residues from structures with an 
open 150-loop conformation are colored green and Asp151 from structures 
with a closed 150-loop conformation are colored blue. PDB IDs: 18N1 – 
3BEQ, avian N1 – 2HTY, Tokyo N2 – 2BAT, N4 - 2HTV, N6 – 1VOZ, 
N8 – 2HT5 and Australia N9 - 1NCA. 
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at release and vice versa. Although immunity is also an im-
portant factor, this may explain why certain HA-NA sero-
type combinations are more common than others and some 
are never observed. Recent data suggests that combination 
of 09N1 with 18H1 results in a higher infectivity, however 
the 09H1 with 18N1 (1918 pandemic N1) does not (Figure 
4) [46]. Because 09H1 and 18H1 are highly similar, it is 
difficult to say the advantage of 18H1 in this system. Per-
haps the stronger basic patch and extra N-glycosylation site 
of 09H1 exerts a significant effect on its function. Further-
more, the propensity of the 150-loop in 09N1 towards the 
closed state may be a major factor in determining the ad-
vantage over the 18N1 in regards to pairing with 18H1. One 
might speculate that if the 09N1 has higher activity than 
18N1 than it is better balanced with 18H1 which may have 
better entry ability than 09H1 (or the opposite situation), 
however further experiments are necessary to arrive at any 
conclusion. 
 
Figure 4  Infectivity of normalized influenza pseudotyped particles (pps) 
with various HA/NA combinations; infectivity is presented as the Mean+/– 
SD percentage of infected cells from 3 repeats. All pps were grouped by 
NA; 2009 H1N1, 1918 H1N1, and H5N1 (A/Anhui/1/2005) are abbrevi-
ated as 09, 1918, and AH, respectively. Reprinted from Zhang et al. [46]. 
There has been a great deal of interest and research into 
the α2,3 and α2,6 specificity of HA and the structural basis 
of substrate binding. Some studies have investigated the 
specificity of various NAs to α2,3 vs α2,6 linked receptor 
substrates [47,48], however no specificity rule for NA has 
been firmly established and the structural basis of the bind-
ing to α2,3 or α2,6 substrates is uncharacterized. The de-
tailed characterization of NA specificity is essential to un-
derstanding HA-NA pairing. Further research regarding the 
receptor recognition of both HA and NA including not only 
specificity but relative affinity and covering a variety of 
prevalent mammalian sialic acid containing receptors will 
provide a strong basis for the mechanisms of HA and NA 
pairing. This will contribute to the comprehensive under-
standing of influenza virus re-assortment. 
The authors thank Dr. Yoshihiro Kawaoka and Dr. Takeshi Noda for pro-
viding the electron micrograph image of influenza virions for our cover 
design. This work was supported by Chinese Academy of Sciences Re-
search Fellowship for Young International Scientists (2010Y2SB12) and 
the National Natural Science Foundation of China for International Young 
Scientists (31050110126) to Vavricka CJ, and the National Natural Sci-
ence Foundation of China (81021003) to Gao GF. 
1 Potter C W. Influenza. Amsterdam, Boston: Elsevier, 2002 
2 Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 
2009 influenza A (H1N1) infection in Canada. JAMA, 2009, 302: 
1872–1879 
3 Wise H M, Foeglein A, Sun J, et al. A complicated message: Identi-
fication of a novel PB1-related protein translated from influenza A 
virus segment 2 mRNA. J Virol, 2009, 83: 8021–8031 
4 Gamblin S J, Skehel J J. Influenza hemagglutinin and neuraminidase 
membrane glycoproteins. J Biol Chem, 2010, 285: 28403–28409 
5 Liu D, Liu X, Yan J, et al. Interspecies transmission and host restric-
tion of avian H5N1 influenza virus. Sci China Life Sci, 2009, 52: 
428–438 
6 Zhang W, Qi J X, Shi Y, et al. Crystal structure of the swine-origin A 
(H1N1) – 2009 influenza A virus hemagglutinin (HA) reveals similar 
antigenicity to that of the 1918 pandemic virus. Protein Cell, 2010, 1: 
459–467 
7 Hay A J, Gregory V, Douglas A R, et al. The evolution of human in-
fluenza viruses. Philos T Roy Soc B, 2001, 356: 1861–1870 
8 Smith G J, Vijaykrishna D, Bahl J, et al. Origins and evolutionary 
genomics of the 2009 swine-origin H1N1 influenza A epidemic. Na-
ture, 2009, 459: 1122–1125 
9 Gao G F, Sun Y. It is not just AIV: From avian to swine-origin in-
fluenza virus. Sci China Life Sci, 2010, 53: 151–153 
10 Neumann G, Noda T, Kawaoka Y. Emergence and pandemic poten-
tial of swine-origin H1N1 influenza virus. Nature, 2009, 459: 931– 
939 
11 Kawaoka Y, Krauss S, Webster R G. Avian-to-human transmission 
of the Pb1 gene of influenza-a viruses in the 1957 and 1968 Pandem-
ics. J Virol, 1989, 63: 4603–4608 
12 WHO. Evolution of H5N1 avian influenza viruses in Asia. Emerg 
Infect Dis, 2005, 11: 1515–1521 
13 Li C J, Hatta M, Nidom C A, et al. Reassortment between avian 
H5N1 and human H3N2 influenza viruses creates hybrid viruses with 
substantial virulence. Proc Natl Acad Sci USA, 2010, 107: 4687– 
4692 
14 Ma W, Lager K M, Vincent A L, et al. The role of swine in the gen-
eration of novel influenza viruses. Zoonoses Public Health, 2009, 56: 
326–337 
15 Nicholls J M, Bourne A J, Chen H, et al. Sialic acid receptor detec-
tion in the human respiratory tract: Evidence for widespread distribu-
tion of potential binding sites for human and avian influenza viruses. 
Respir Res, 2007, 8: 73 
16 Nelli R K, Kuchipudi S V, White G A, et al. Comparative distribution 
of human and avian type sialic acid influenza receptors in the pig. 
BMC Vet Res, 2010, 6: 4 
17 Shinya K, Ebina M, Yamada S, et al. Avian flu: Influenza virus re-
ceptors in the human airway. Nature, 2006, 440: 435–436 
18 Zhao G P, Zhong Y. Learn to fight from the war. Chinese Sci Bull, 
2009, 54: 2157–2158 
19 Kou Z, Hu S N, Li T X. Genome evolution of novel influenza A 
(H1N1) viruses in humans. Chinese Sci Bull, 2009, 54: 2159–2163 
20 Chen J M, Sun Y X, Liu S, et al. Origin and future distribution of the 
new A (H1N1) influenza virus emerging in North America in 2009. 
Chinese Sci Bull, 2009, 54: 2174–2178 
21 Wu B, Wang C M, Dong G Y, et al. Molecular characterization of 
H1N1 influenza A viruses from human cases in North America. Chi-
nese Sci Bull, 2009, 54: 2179–2192 
22 Skehel J J, Wiley D C. Receptor binding and membrane fusion in vi-
rus entry: The influenza hemagglutinin. Annu Rev Biochem, 2000, 
69: 531–569 
23 Wu D, Xu T L, Sun J, et al. Structure modeling and spatial epitope 
analysis for HA protein of the novel H1N1 influenza virus. Chinese 
Sci Bull, 2009, 54: 2171–2173 
24 Yan A, Ding G H, Zhou Z F, et al. Subtyping of type A influenza by 
sequencing the variable regions of HA gene specifically amplified 
1752 Vavricka C J, et al.   Chinese Sci Bull   June (2011) Vol.56 No.17 
with RT-PCR. Chinese Sci Bull, 2009, 54: 2164–2167 
25 He Y G, Ding G H, Bian C, et al. The mutation network for the he-
magglutinin gene from the novel influenza A (H1N1) virus. Chinese 
Sci Bull, 2009, 54: 2168–2170 
26 Xu R, Ekiert D C, Krause J C, et al. Structural basis of preexisting 
immunity to the 2009 H1N1 pandemic influenza virus. Science, 
2010, 328: 357–360 
27 Yang H, Carney P, Stevens J. Structure and receptor binding proper-
ties of a pandemic H1N1 virus hemagglutinin. PLoS Curr Influenza, 
2010, 2: RRN1152 
28 Wrammert J, Koutsonanos D, Li G M, et al. Broadly cross-reactive an-
tibodies dominate the human B cell response against 2009 pandemic 
H1N1 influenza virus infection. J Exp Med, 2011, 208: 181–193 
29 Wang C C, Chen J R, Tseng Y C, et al. Glycans on influenza hemag-
glutinin affect receptor binding and immune response. Proc Natl 
Acad Sci USA, 2009, 106: 18137–18142 
30 Matrosovich M N, Matrosovich T Y, Gray T, et al. Human and avian 
influenza viruses target different cell types in cultures of human air-
way epithelium. Proc Natl Acad Sci USA, 2004, 101: 4620–4624 
31 Stevens J, Blixt O, Glaser L, et al. Glycan microarray analysis of the 
hemagglutinins from modern and pandemic influenza viruses reveals 
different receptor specificities. J Mol Biol, 2006, 355: 1143–1155 
32 Gamblin S J, Haire L F, Russell R J, et al. The structure and receptor 
binding properties of the 1918 influenza hemagglutinin. Science, 
2004, 303: 1838–1842 
33 Reid A H, Janczewski T A, Lourens R M, et al. 1918 influenza pan-
demic caused by highly conserved viruses with two receptor-binding 
variants. Emerg Infect Dis, 2003, 9: 1249–1253 
34 Tumpey T M, Maines T R, Van Hoeven N, et al. A two-amino acid 
change in the hemagglutinin of the 1918 influenza virus abolishes 
transmission. Science, 2007, 315: 655–659 
35 Liu Y, Childs R A, Matrosovich T, et al. Altered receptor specificity 
and cell tropism of D222G hemagglutinin mutants isolated from fatal 
cases of pandemic A (H1N1) 2009 influenza virus. J Virol, 2010, 84: 
12069–12074 
36 Sun Y, Shi Y, Zhang W, et al. In silico characterization of the func-
tional and structural modules of the hemagglutinin protein from the 
swine-origin influenza virus A (H1N1)-2009. Sci China Life Sci, 
2010, 53: 633–642 
37 Stevens J, Corper A L, Basler C F, et al. Structure of the uncleaved 
human H1 hemagglutinin from the extinct 1918 influenza virus. Sci-
ence, 2004, 303: 1866–1870 
38 Russell R J, Haire L F, Stevens D J, et al. The structure of H5N1 
avian influenza neuraminidase suggests new opportunities for drug 
design. Nature, 2006, 443: 45–49 
39 Li Q, Qi J, Zhang W, et al. The 2009 pandemic H1N1 neuraminidase 
N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol, 2010, 
17: 1266–1268  
40 Amaro R E, Minh D D, Cheng L S, et al. Remarkable loop flexibility 
in avian influenza N1 and its implications for antiviral drug design. J 
Am Chem Soc, 2007, 129: 7764–7765 
41 von Itzstein M. The war against influenza: Discovery and develop-
ment of sialidase inhibitors. Nat Rev Drug Discov, 2007, 6: 967–974 
42 Varghese J N, Smith P W, Sollis S L, et al. Drug design against a 
shifting target: A structural basis for resistance to inhibitors in a 
variant of influenza virus neuraminidase. Structure, 1998, 6: 735–746 
43 Amaya M F, Watts A G, Damager I, et al. Structural insights into the 
catalytic mechanism of Trypanosoma cruzi trans-sialidase. Structure, 
2004, 12: 775–784 
44 Watts A G, Oppezzo P, Withers S G, et al. Structural and kinetic 
analysis of two covalent sialosyl-enzyme intermediates on Trypano-
soma rangeli sialidase. J Biol Chem, 2006, 281: 4149–4155 
45 Watts A G, Damager I, Amaya M L, et al. Trypanosoma cruzi trans- 
sialidase operates through a covalent sialyl-enzyme intermediate: 
Tyrosine is the catalytic nucleophile. J Am Chem Soc, 2003, 125: 
7532–7533 
46 Zhang Y, Lin X, Wang G, et al. Neuraminidase and hemagglutinin 
matching patterns of a highly pathogenic avian and two pandemic 
H1N1 influenza A viruses. PLoS ONE, 2010, 5: e9167 
47 Katinger D, Mochalova L, Chinarev A, et al. Specificity of neura-
minidase activity from influenza viruses isolated in different hosts 
tested with novel substrates. Arch Virol, 2004, 149: 2131–2140 
48 Xu G, Suzuki T, Maejima Y, et al. Sialidase of swine influenza A vi-
ruses: Variation of the recognition specificities for sialyl linkages and 
for the molecular species of sialic acid with the year of isolation. 
Glycoconj J, 1995, 12: 156–161 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
 
